Overview

Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy

Status:
Unknown status

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to elucidate the influence of anti-hepatitis B virus therapy on safety and survival of HCC patient after transcatheter arterial chemoembolization.

Phase:

Phase 4

Details

Lead Sponsor:

Fudan University

Treatments:

Telbivudine